Evaxion launches AI-powered vaccine design platform module.

Evaxion, a clinical-stage TechBio company, has launched an improved version of its AI-platform, AI-Immunology™, with a new automated vaccine design module. The module automates previous manual vaccine design processes, improving quality and reducing time and resource requirements. The platform is now capable of enhanced design applicable for both new vaccines and optimization of approved ones. Evaxion will present detailed validation data on these improvements at the World Vaccine Congress Europe on October 15, 2025.

Evaxion, a clinical-stage TechBio company, has announced a significant advancement in its AI-Immunology™ platform with the launch of an automated vaccine design module. This new feature automates previous manual vaccine design processes, enhancing the quality of vaccine designs and reducing time and resource requirements.

The automated vaccine design module integrates target discovery and design into an end-to-end workflow, ensuring correct antigen sequence and conformation. This innovation aims to improve vaccine quality and reduce design time from months to days, leading to substantial cost savings. The module can be applied to both new vaccines and the optimization of existing ones, thereby expanding the platform's product scope.

Evaxion will present detailed validation data on these improvements at the World Vaccine Congress Europe in Amsterdam on October 15, 2025. The company expects to showcase test results confirming the enhanced capabilities of the AI-Immunology™ platform.

The new module addresses common issues encountered with traditional manual design methods, such as ensuring proper expression and conformation of vaccine targets. By automating these processes, Evaxion aims to enhance the efficiency and effectiveness of vaccine development.

Evaxion's Chief Scientific Officer and interim CEO, Birgitte Rønø, expressed excitement about the launch, stating, "We are very excited to launch this latest improvement of AI-Immunology™, achieving yet another of our milestones for 2025. The new modules significantly enhance our value proposition towards potential partners and increase our in-house capabilities."

The company will present its findings at the World Vaccine Congress Europe, where key test results will be shared. The presentation is titled "Antigen optimization for infectious disease vaccines using AI-Immunology™" and will be delivered by Thomas Trolle, PhD, Director of Bioinformatics & AI/ML at Evaxion.

Evaxion is a pioneer in AI-driven vaccine discovery and design, leveraging its proprietary and scalable AI prediction models to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. The company's AI-Immunology™ platform has been instrumental in developing a clinical-stage oncology pipeline and a preclinical infectious disease pipeline with high unmet medical needs.

The launch of the automated vaccine design module underscores Evaxion's commitment to innovation and its strategic focus on expanding its platform's capabilities. Investors and financial professionals should closely monitor Evaxion's progress and the validation data to be presented at the World Vaccine Congress Europe.